Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs. Connecting patients directly to medical research and incentivizing them to share their data with tokens, blockchain is the decentralized technology everyone was waiting for to move away from the current linear process of drug approvals, to a new iterative model where trustworthy digital health data is shared in real time between patients, life sciences and regulators. The 21st Century Cures Act (2016) gave the FDA a mandate to accelerate approvals if more patient real world data was shared proactively by pharma. Embleema’s blockchain speeds up this process with patient buy-in, accelerating time to market new drugs.

Click to see more

ICO’s Details

  • GENERAL INFORMATION
  • Pre-ICO Opening Date:

    Thu, Oct 10th, 2019 12:00 AM

  • Pre-ICO Closing Date:

    Wed, Jan 1st, 2020 12:00 AM

  • ICO Opening Date:

    To be announced

  • ICO Closing Date:

    To be announced

  • Country of Origin:

    France

  • TOKEN DETAILS
  • Symbol:

    RWE

  • Blockchain Type:

    Ethereum

  • Platform:

    ERC20

Team

Robert Chu - CEO and CTO, former head of IMS / IQVIA in France & China, SVP of Technology Solutions
Alexis Normand - Head of Embleema Consortium, former Head of B2B Nokia Digital health / Withings
Pradeep Sreekanthan - Chief Delivery Officer, Former Director at IMS Health
Prashant Khambekar, Ph.D - Chief Development Executive, SVP Harbringer Systems
Nicolas Schmidt - Chief Product Officer, former head of Healthcare Products at Nokia
Vincent Galand - Operations Manager France
Lorenzo Nardiello - Social Media Manager
Xavier Lavayssière - Blockchain Regulation and Smart Contracts Expert
Munair Simpson - ICO & Crypto Expert - Asia

Advisors

Dr. Vahan Simonyan - Chief Scientific Advisor, former R&D Director of Bioinformatics at the FDA
Pr. John Halamka, MD - CIO of Beth Israel, Pr. of Innovation at Harvard
Bernard Gilly, PhD - CEO of iBionext - Pixum -
Frédéric Duchesne, Pharm.D - CEO of Pierre Fabre Pharmaceuticals
Adel B. Al-Saleh - CEO T-Systems

Featured Video

Disclosure: This page is created to provide market intelligence. This is not investment advice and does not constitute any solicitation or endorsement of any investment. Any investment you make is done at your own risk and at your full and absolute discretion.